DexCom, Inc. DXCM raised its 2026 revenue and margin outlook after a stronger second quarter, shifting more attention toward profitability. The question is whether better gross margin and operating leverage can persist as organic growth improves.
The guidance increase is encouraging, but foreign exchange, manufacturing investment and product-transition costs still matter. Sustaining the margin step-up will require continued execution across products, geographies and channels.
DexCom’s Q2 Results Reset the 2026 Baseline
DexCom reported second-quarter 2026 revenues of $1.31 billion, up 13.1% year over year, while adjusted earnings reached 70 cents per share. Adjusted operating income increased 48% to $328.3 million, with the adjusted operating margin expanding to 25.1%.
The operating backdrop was broad. U.S. revenues rose 11% to $933.4 million, while international revenues increased 19% to $375 million. International organic growth was 16%, supported by reimbursement expansion and adoption in markets including France and Canada.
DXCM’s Raised Margin Outlook Shows Better Leverage
Management now expects 2026 revenues of $5.18-$5.25 billion, up from the prior $5.16-$5.25 billion range. The updated outlook implies 11-13% annual growth and incorporates stronger organic growth expectations.
Profitability guidance moved higher as well. DexCom raised its adjusted gross margin forecast to about 64%, adjusted operating margin guidance to 23.5%-24% and adjusted EBITDA margin guidance to 31.5%-32%. Those revisions make operating leverage a larger part of the 2026 thesis rather than leaving the story dependent mainly on revenue growth.
DexCom’s G7 15 Day Rollout Supports Profitability
The G7 15 Day transition is helping the margin profile through product mix and manufacturing efficiency. Second-quarter adjusted gross margin reached 64.1%, up 400 basis points year over year, as manufacturing efficiencies and the initial customer switchover to G7 15 Day supported results.
The rollout also broadens the product opportunity. DexCom expects to convert nearly half of its U.S. customer base to G7 15 Day by year-end 2026. Health Canada has cleared the system, while Dexcom Flex has launched in Germany, giving the company additional paths to extend 15-day sensor economics internationally.
DXCM’s FX and Execution Risks Could Offset Progress
The higher outlook still carries offsets. DexCom expects a roughly $15 million foreign-exchange headwind to second-half 2026 international revenues. The company is also investing in its Ireland manufacturing facility, while the transition away from G6 brings inventory and execution costs that can complicate near-term efficiency gains.
Competition can further influence pricing, rebates and channel mix. Abbott Laboratories ABT continues to expand its FreeStyle Libre continuous glucose monitoring franchise, including use in type 2 diabetes. Senseonics Holdings, Inc. SENS markets the implantable Eversense 365 system, giving patients and payers another differentiated continuous glucose monitoring option.
DexCom’s Signal Check Keeps Expectations Grounded
The margin upgrades improve DXCM’s fundamental setup, and earnings estimates have moved higher. Over the past 60 days, estimates for 2026 and 2027 rose 2.7% and 1.2% to $2.65 and $3.08 per share, respectively. The stock, however, trades at 30.7X forward 12-month earnings, above 27.3X for the Zacks sub-industry, 21.2X for the Medical sector and 20.7X for the S&P 500.
Image Source: Zacks Investment Research
DXCM currently carries a Zacks Rank #3 (Hold). Likewise, Abbott and Senseonics carry a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Raised guidance and improving estimates support the margin story, but the valuation premium, foreign-exchange pressure and execution demands keep the case balanced rather than decisively bullish.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Â
Â
Â
(0) comments
Welcome to the discussion.
Log In
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.